Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment

Chronic myeloid leukemia (CML) is characterized by the constitutive tyrosine kinase activity of the oncoprotein BCR-ABL1 in myeloid progenitor cells that activates multiple signal transduction pathways leading to the leukemic phenotype. The tyrosine-kinase inhibitor (TKI) nilotinib inhibits the tyro...

Descripción completa

Detalles Bibliográficos
Autores principales: Trojani, Alessandra, Pungolino, Ester, Dal Molin, Alessandra, Lodola, Milena, Rossi, Giuseppe, D’Adda, Mariella, Perego, Alessandra, Elena, Chiara, Turrini, Mauro, Borin, Lorenza, Bucelli, Cristina, Malato, Simona, Carraro, Maria Cristina, Spina, Francesco, Latargia, Maria Luisa, Artale, Salvatore, Spedini, Pierangelo, Anghilieri, Michela, Di Camillo, Barbara, Baruzzo, Giacomo, De Canal, Gabriella, Iurlo, Alessandra, Morra, Enrica, Cairoli, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6638825/
https://www.ncbi.nlm.nih.gov/pubmed/31318870
http://dx.doi.org/10.1371/journal.pone.0218444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6638825/
https://www.ncbi.nlm.nih.gov/pubmed/31318870
http://dx.doi.org/10.1371/journal.pone.0218444

Ejemplares similares